Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith is the details of Analyst/ Institutional Investor meeting to be conducted. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor meetings to be conducted. Alkem Laboratories Ltd - 539523 - Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure on a consolidated basis, for the half year ended on 30th September, 2022 in the prescribed format. The same have been published on the website of the Company at www.alkemlabs.com. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor meetings to be conducted. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We enclose herewith the transcript of the 'Q2 FY2023 Earnings Conference Call' which was hosted by the Company on Friday, 11th November, 2022. The said transcript shall also be made available on the website of the Company. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the 'Q2FY23 Earnings Conference Call' is available on the website of the Company at https://www.alkemlabs.com/earnings-call.php. Kindly take the same on records. Q2FY23 Quarterly Result Announced for Alkem Laboratories Ltd.
Pharmaceutical company Alkem Laboratories announced Q2FY23 results: Q2FY23: Total revenue from operations was Rs 30,793 million, with YoY growth of 10.0% India sales were Rs 22,161 million, with YoY growth of 13.0% International sales were Rs 8,291 million, with YoY growth of 3.0% Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 4,539 million, resulting in EBITDA margins of 14.7% vs 22.3% in Q2FY22. EBITDA declined by 27.3% YoY R&D; expenses for the quarter were Rs 1,305 million, or 4.2% of total revenue from operations compared to Rs 1,407 million in Q2FY22 at 5.0% of total revenue from operations Profit before tax (PBT) was Rs 4,023 million, a decline of 30.8% compared to Q2FY22 Net profit (after Minority Interest) was Rs 3,308 million, a YoY decline of 39.2% H1FY23: Total revenue from operations was Rs 56,558 million, with YoY growth of 2.2% India sales were Rs 39,976 million, with YoY growth of 3.3% International sales were Rs 15,895 million, a YoY decline of 0.4% EBITDA was Rs 6,572 million, resulting in an EBITDA margin of 11.6% vs 22.0% in H1FY23. EBITDA declined by 46.0% YoY R&D; expenses for H1FY23 were Rs 2,625 million, or 4.6% of total revenue from operations compared to Rs 2,590 million in H1FY22 at 4.7% of total revenue from operations Profit before tax (PBT) was Rs 5,542 million, a decline of 51.3% compared to H1FY22 Net profit (after Minority Interest) was Rs 4,585 million, a YoY decline of 54.7% Sandeep Singh, Managing Director, Alkem, said, “After a market-beating performance in Q1, our domestic franchise has significantly outperformed IPM even in Q2. We increased market share across all acute therapies, anti-diabetic and urology during this quarter. While our US business continues to face significant pricing pressure, our other international business is growing at a healthy pace. Various cost optimisation initiatives are underway which should help in building sustainable and profitable business and also drive margin expansion. We are receiving encouraging response for our biosimilar and CDMO franchise." Result PDF Alkem Laboratories Ltd - 539523 - Closure of Trading Window
We refer to our earlier communication dated 28th September, 2022 regarding closure of trading window (for the purpose of financial results for the quarter ended 30th September, 2022) starting from 29th September, 2022 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended 30th September, 2022 are communicated to the Stock Exchanges. The Financial Results of the Company for the quarter and half year ended 30th September, 2022 having been communicated to the Stock Exchanges, today i.e. 11th November, 2022, the trading window shall open on 14th November, 2022. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q2FY23 earnings and business updates and the same will be uploaded on the website of the Company. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Announcement Under Regulation 30 (LODR)- Cut-Off Date For Postal Ballot
This is to inform you that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, the Board of Directors of the Company at its meeting held today i.e. 11th November, 2022 have decided to seek approval of the shareholders by way of Postal Ballot through remote e-voting for re-appointment of Mr. Mritunjay Kumar Singh (DIN: 00881412) as an Executive Director of the Company, liable to retire by rotation, for a period of 5 consecutive years w.e.f. 01.01.2023 upto 31.12.2027. The Company has fixed Friday, 25th November, 2022 as cut-off date for ascertaining the eligibility of shareholders for dispatch of Postal Ballot Notice and remote voting through electronic means. Kindly take note of the same.